The RECIST-evaluable patients included patients ... have been implicated as important in castration-resistant prostate cancer. Synergistic anti-tumor activity has been reported with the sequential ...

The RECIST-evaluable patients included patients ... have been implicated as important in castration-resistant prostate cancer. Synergistic anti-tumor activity has been reported with the sequential ...

The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu ... in 40% to 60% of patients, and a RECIST response rate in soft tissue ...

Dana Rathkopf addresses the intensification of systemic treatment in poor-risk prostate cancer patients experiencing biochemical ... demonstrated promising PSA and RECIST responses in heavily ...

225 Ac has been evaluated over the past few years across numerous prostate cancer settings, including mHSPC ... 80% of patients had a response, per RECIST criteria (stable disease, partial/complete ...

It’s tough for a man to know what to do following a diagnosis of prostate cancer.The treatment is often worse than the ...

The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancerscreeningis highly accurate. The exciting new results, published in The Journal ...

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate.

A recent study finds that genetically predicted rheumatoid arthritis is causally associated with prostate cancer.

Following a change in screening guidelines, the incidence went up across the state, even more than it has nationally.

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...